VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

VJVirtual | ELEVATE CLL TN & ASCEND: acalabrutinib in CLL

Toby Eyre, MD, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), Oxford University Hospitals NHS Foundation Trust, Oxford, UK, shares an update on two randomized clinical trials of acalabrutinib in chronic lymphocytic leukemia (CLL). The ELEVATE CLL TN trial (NCT02475681) is investigating obinutuzumab plus chlorambucil versus acalabrutinib plus obinutuzumab or acalabrutinib monotherapy in patients with treatment-naïve CLL. The ASCEND trial (NCT02970318) is comparing acalabrutinib versus investigator’s choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory CLL. Dr Eyre discusses the results of these trials, highlighting progression-free survival (PFS) benefits in the acalabrutinib arms and outlines the implications of these findings for clinical practice.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter